7B: Biomaterials for Cancer Immunotherapy
Time: 8:00 AM to 10:00 AM
Description
The past decade has witnessed the roaring development of immunotherapies for clinical cancer treatment. Immune checkpoint blockade therapies and chimeric antigen receptor (CAR)-T cell therapies have demonstrated clinical efficacy against a variety of cancers. However, issues including limited patient responses, life-threatening off-target side effects, and poor efficacy against many solid tumors still limit the clinical utility of cancer immunotherapies. Biomaterial carriers of these therapies, though, enable one to troubleshoot the delivery issues, amplify immunomodulatory effects, integrate the synergistic effect of different molecules, and more importantly, home and manipulate immune cells in vivo. Through this “Biomaterials for Cancer Immunotherapy” symposium in 2025 SFB Annual Meeting, we aim to bring together scientists pursuing cutting edge research at the intersection of biomaterials and cancer immunotherapy. Topics of interest include but are not limited to: nanovaccine, nano-immunotherapy, biomaterial scaffold immunotherapy, adjuvanting materials, materials for immune cell engineering, immunological modeling systems, and lymphoid organoids.
Moderators:
Hua Wang, University of Illinois Urbana-Champaign
Brian Kwee, University of Delaware
Objectives
8:00 AM. 318. Engineering A Biomaterials-based Lymphoid Niche for mRNA Lipid Nanoparticle Cancer Vaccines.Yining Zhu, M.S.E.1, Zhi-Cheng Yao1, Jingyao Ma1, Christine Wei1, Hai-Quan Mao1 1Johns Hopkins University
8:15 AM. 319. Injectable adhesive hydrogel-based in situ vaccines eliminate established brain tumors by stimulating innate and adaptive immune responses that are enhanced by sustained release kinetics.Michelle Dion1, Alexander Cryer, PhD2, Daniel Dahis, PhD3, Pere Dosta, PhD4, Natalie Artzi, PhD5 1Harvard-MIT, 2Brigham and Women's Hospital, 3BWH, 4UTSW, 5Harvard Medical School
8:30 AM. 320. Restoration of cGAS in tumor cells promotes antitumor immunity via transfer of tumor-cell generated cGAMP.Alexander Cryer, PhD1, Pere Dosta, PhD2, Michelle Dion3, Eliz Amar-Lewis, PhD1, Natalie Artzi, PhD4 1Brigham and Women's Hospital, 2University of Texas Southwestern, 3Harvard-MIT, 4Harvard Medical School
8:45 AM. 321. Cancer vaccination using cell-mediated delivery of an adjuvant loaded via ionic liquid cocktail.Danika Rodrigues1, Kyung Soo Park2, Malini Mukherji1, Maithili Joshi1, Suyog Shaha1, Litsa Kapsalis3, Samir Mitragotri1 1Harvard University, 2Harvard Unversity, 3Harvard College
9:00 AM. 322. Clickable Nanoplex Cluster-Mediated Synergistic Modulation of Dendritic Cells and T Cells Amplifies Tumor-Specific Adaptive Immunity.Wei Mao1, Hyuksang Yoo2 1Knagwon National University, 2Kangwon National University
9:15 AM. 323. Plasmid DNA Vaccine for Post-Surgical Immunotherapy Against Murine Melanoma.Trishita Chowdhury1, Vanshika Singh1, Sudhakar Godeshala, PhD1, Jordan Yaron, PhD1, Kaushal Rege, PhD1 1Arizona State University
9:30 AM. 324. Inhalable Unnatural Sugar for Tagging and Targeting of Lung Cancer Cells.Jiadiao (David) Zhou1, Hua Wang2 1University of Illinois Urbana Champaign, 2University of Illinois
9:45 AM. 325. Macroporous Hydrogel-Based mRNA Cancer Vaccine for In Situ Recruitment and Modulation of Dendritic Cells.Ruike Dai1, Jiadiao (David) Zhou2, Hua Wang3 1University of Illinois at Urbana-Champaign, 2University of Illinois Urbana Champaign, 3University of Illinois